Williams, 70, has to pay nearly $180,000 for his cancer therapy, of which more than $25,000 will go on GST. “It’s a tax on ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be ...

A new independent academic study examining a form of blood cancer among those who served at Malmstrom Air Force Base, Montana ...

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

An FDA-designated orphan drug that can target a key vulnerability in lung cancer shows promise in improving the efficacy of ...

Preliminary results from the AACR 2025 Annual Meeting reveal encouraging clinical responses to the investigational oral agent ...

Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the ...

The combined company has been renamed Liminatus Pharma, Inc., and its common stock and warrants are expected to commence trading on The Nasdaq Stock Market LLC (“Nasdaq”) under the new ticker symbols ...

How one man, along with his care team, turned an all-consuming cancer diagnosis into a management strategy with inspiration ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

The American Association for Cancer Research’s annual conference continued Tuesday with Marengo Therapeutics making progress ...

Surgery remains the mainstay of treatment for early-stage [non-small cell lung cancer (NSCLC)], regardless of age,” researchers wrote in the Journal of ...